Literature DB >> 19371475

Radiation therapy approaches to the treatment of high-risk prostate cancer.

Soroush Rais-Bahrami1, Manish A Vira, Louis Potters.   

Abstract

Radiation therapy modalities have been shown to offer patients a nonoperative option for definitive treatment of localized prostate cancer as well as options for adjuvant or salvage therapy in high-risk prostate cancer patients. In patients with high-risk, localized disease, radiation therapy with or without adjuvant hormonal therapy is considered an excellent treatment option because of its efficacy within the prostate and among local periprostatic structures, addressing micrometastatic disease. Following radical prostatectomy in patients with high-risk or recurrent disease, radiotherapy can increase oncologic efficacy in both the adjuvant and salvage setting. Continued studies are underway to address ongoing concerns of sparing surrounding tissues unnecessary radiation while administering high-dose radiation to the prostate and targeted periprostatic structures. Newer technologies are using real-time imaging and computer-simulated motion calculation to adjust for physiological organ motion with respect to bony landmarks classically used to map areas of radiation administration.

Entities:  

Mesh:

Year:  2009        PMID: 19371475     DOI: 10.1007/s11934-009-0032-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  46 in total

1.  External beam radiation therapy of primary carcinoma of the prostate.

Authors:  M A Bagshaw; G R Ray; D A Pistenma; R A Castellino; E M Meares
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

2.  Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?

Authors:  K Kenneth Chao; Neal S Goldstein; Di Yan; Carlos E Vargas; Michel I Ghilezan; Howard J Korman; Kenneth M Kernen; Jay B Hollander; Jose A Gonzalez; Alvaro A Martinez; Frank A Vicini; Larry L Kestin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

3.  Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model.

Authors:  C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.

Authors:  Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

5.  Long-term outcomes in younger men following permanent prostate brachytherapy.

Authors:  Edan Y Shapiro; Soroush Rais-Bahrami; Carol Morgenstern; Barbara Napolitano; Lee Richstone; Louis Potters
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

6.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

8.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Authors:  Razvan M Galalae; Alvaro Martinez; Tim Mate; Christina Mitchell; Gregory Edmundson; Nils Nuernberg; Stephen Eulau; Gary Gustafson; Michael Gribble; Gyoergy Kovács
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

9.  Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.

Authors:  Colleen A Lawton; Kyoungwha Bae; Miljenko Pilepich; Gerald Hanks; William Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-19       Impact factor: 7.038

10.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

Authors:  Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-04       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.